Novavax Plunges Amid Dismay Over Timeline for Covid-19 Shot (2)

Novavax Inc. shares extended declines after the close of trading Monday following first-quarter results in which the company said it doesn’t plan to file for authorization for its Covid-19 vaccine in the U.S. and Europe until the third quarter.

The firm’s stock fell more than 11% post-market following an 8.8% decline during the session that came on the heels of a Washington Post report that said the biotech’s plans to seek emergency use authorization for its closely-watched Covid-19 vaccine would be delayed.

The drug developer will not publish results from a highly-anticipated study of the vaccine until the end of ...